Literature DB >> 1806545

Lipoprotein immune complexes as markers of atherosclerosis.

A N Orekhov1, O S Kalenich, V V Tertov, I D Novikov.   

Abstract

Recently we have demonstrated that cholesterol level in LDL-containing circulating immune complexes (CIC cholesterol) correlates with the presence of coronary atherosclerosis. In the present study we attempted to clarify whether CIC cholesterol level correlates with the severity of coronary atherosclerosis. The second task was to reveal the diagnostic value of CIC cholesterol in comparison with other lipid and lipoprotein parameters used as markers of dislipidaemia associated with atherosclerosis. The subjects were 107 patients with angiographically-documented coronary atherosclerosis and 66 patients with documented extracoronary atherosclerosis. Only CIC cholesterol and the apo B/apo A-1 ratio contributed strongly to the discrimination between patients with coronary atherosclerosis and those without stenoses. On the other hand, total cholesterol, triglycerides, HDL cholesterol, apo B, Lp[a] and apo A1 did not correlate with the presence and severity of coronary atherosclerosis. Subjects with stenosis of extracoronary arteries had significantly higher CIC levels than healthy donors. Sensitivity, specificity and accuracy of coronary atherosclerosis diagnosis were assessed for each parameter examined. It was revealed that CIC cholesterol is the most reliable marker of coronary atherosclerosis as compared to other chemical parameters. In addition, the CIC cholesterol level diagnoses extracoronary atherosclerosis with high accuracy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1806545

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  9 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 3.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

4.  A Method for In Vitro Measurement of Oxidized Low-Density Lipoprotein in Blood, Using Its Antibody, Fluorescence-Labeled Heptapeptide and Polyethylene Glycol.

Authors:  Akira Sato; Yoji Yamazaki; Keiichi Ebina
Journal:  J Fluoresc       Date:  2017-07-07       Impact factor: 2.217

5.  Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.

Authors:  Igor A Sobenin; Vasily P Karagodin; Alexandra Capital A Cyrillic Melnichenko; Yuri V Bobryshev; Alexander N Orekhov
Journal:  J Clin Immunol       Date:  2012-10-17       Impact factor: 8.317

Review 6.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

7.  The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-15       Impact factor: 5.555

Review 8.  Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach.

Authors:  Alexander N Orekhov; Igor A Sobenin; Victor V Revin; Yuri V Bobryshev
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

Review 9.  Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.

Authors:  Igor A Sobenin; Jukka T Salonen; Andrey V Zhelankin; Alexandra A Melnichenko; Jari Kaikkonen; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Biomed Res Int       Date:  2014-06-18       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.